Evaluation and prospects for the introduction of VMAT for the purpose of reducing pericardial effusion after radical CRT for esophageal cancer

Comparison of adverse events in esophageal cancer patients treated with definitive CRT using between 3DCRT and VMAT combination - Adverse events of VMAT in thoracic CRT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043452

Enrollment

120

Registered

2021-06-30

Start date

2012-04-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic esophageal squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Thoracic esophageal squamous cell carcinoma Treated with definitive CRT Given boost 9Gy after 50.4Gy ENI

Exclusion criteria

Exclusion criteria: Age is over 80 years old Chemotherapy cannot be given due to complications

Design outcomes

Primary

Measure	Time frame
Dosimetric analyses by irradiation methods reveals observations regarding pericardial effusion after chemoradiation	—

Countries

Japan

Contacts

Public ContactMiyako Myojin

Keiyukai Sapporo Hospital Division of radiation oncology

miyako98kazm@gmail.com0118632101

Outcome results